MX2014003325A - Vacunoterapia. - Google Patents
Vacunoterapia.Info
- Publication number
- MX2014003325A MX2014003325A MX2014003325A MX2014003325A MX2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A MX 2014003325 A MX2014003325 A MX 2014003325A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid
- vaccine therapy
- young
- syndrome
- protein
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 3
- 206010044688 Trisomy 21 Diseases 0.000 abstract 3
- 230000007170 pathology Effects 0.000 abstract 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona medios para tratar, aliviar y prevenir una patología relacionada con amiloideos en sujetos desde jóvenes hasta edad intermedia con síndrome de Down (DS). En particular, la presente invención proporciona fragmentos de péptido antigénico derivados de una proteína amiloidea o una proteína similar a amiloidea para el uso en el tratamiento preventivo de una patología relacionada con amiloideos en sujetos desde jóvenes hasta edad intermedia, con síndrome de Down.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/052992 | 2011-09-23 | ||
| PCT/US2012/056728 WO2013044147A1 (en) | 2011-09-23 | 2012-09-21 | Vaccine therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014003325A true MX2014003325A (es) | 2014-05-21 |
| MX350928B MX350928B (es) | 2017-09-26 |
Family
ID=47018510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003325A MX350928B (es) | 2011-09-23 | 2012-09-21 | Vacunoterapia. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240270829A1 (es) |
| EP (1) | EP2758071B1 (es) |
| JP (1) | JP6110861B2 (es) |
| KR (3) | KR102129220B1 (es) |
| CN (2) | CN109847058A (es) |
| AU (1) | AU2012312126B2 (es) |
| BR (1) | BR112014006871A2 (es) |
| CA (1) | CA2811188C (es) |
| DK (1) | DK2758071T3 (es) |
| EA (1) | EA032494B1 (es) |
| ES (1) | ES2712951T3 (es) |
| HU (1) | HUE041277T2 (es) |
| IL (1) | IL231564A0 (es) |
| MX (1) | MX350928B (es) |
| MY (1) | MY169574A (es) |
| PL (1) | PL2758071T3 (es) |
| PT (1) | PT2758071T (es) |
| SG (1) | SG11201400795UA (es) |
| SI (1) | SI2758071T1 (es) |
| TR (1) | TR201901846T4 (es) |
| WO (1) | WO2013044147A1 (es) |
| ZA (1) | ZA201402071B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150646A1 (es) | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| TW202110425A (zh) | 2019-05-21 | 2021-03-16 | 瑞士商Ａｃ 免疫有限公司 | 抗Ａβ疫苗治療 |
| WO2024156912A1 (en) | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9123998A (en) | 1997-08-28 | 1999-03-16 | Ajay North America | Methods and compositions for protecting plants and crops |
| MXPA05006940A (es) | 2002-12-24 | 2006-02-22 | Neurochem Int Ltd | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| AR047062A1 (es) * | 2003-12-17 | 2006-01-04 | Wyeth Corp | Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos |
| KR20070040824A (ko) * | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
| CN101330923B (zh) * | 2005-12-12 | 2015-01-07 | Ac免疫有限公司 | 治疗性疫苗 |
| WO2008156621A1 (en) * | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
-
2011
- 2011-09-23 KR KR1020197008710A patent/KR102129220B1/ko active IP Right Grant
- 2011-09-23 KR KR1020137002631A patent/KR20160005380A/ko active Application Filing
- 2011-09-23 KR KR1020167021791A patent/KR20160099732A/ko active Application Filing
- 2011-09-23 CA CA2811188A patent/CA2811188C/en active Active
-
2012
- 2012-09-21 CN CN201910160828.6A patent/CN109847058A/zh active Pending
- 2012-09-21 PL PL12772616T patent/PL2758071T3/pl unknown
- 2012-09-21 PT PT12772616T patent/PT2758071T/pt unknown
- 2012-09-21 AU AU2012312126A patent/AU2012312126B2/en active Active
- 2012-09-21 EP EP12772616.4A patent/EP2758071B1/en active Active
- 2012-09-21 EA EA201400376A patent/EA032494B1/ru not_active IP Right Cessation
- 2012-09-21 DK DK12772616.4T patent/DK2758071T3/en active
- 2012-09-21 MX MX2014003325A patent/MX350928B/es active IP Right Grant
- 2012-09-21 ES ES12772616T patent/ES2712951T3/es active Active
- 2012-09-21 CN CN201280057432.5A patent/CN104039346A/zh active Pending
- 2012-09-21 JP JP2014532040A patent/JP6110861B2/ja active Active
- 2012-09-21 SG SG11201400795UA patent/SG11201400795UA/en unknown
- 2012-09-21 MY MYPI2014000851A patent/MY169574A/en unknown
- 2012-09-21 HU HUE12772616A patent/HUE041277T2/hu unknown
- 2012-09-21 TR TR2019/01846T patent/TR201901846T4/tr unknown
- 2012-09-21 BR BR112014006871A patent/BR112014006871A2/pt not_active Application Discontinuation
- 2012-09-21 WO PCT/US2012/056728 patent/WO2013044147A1/en active Application Filing
- 2012-09-21 SI SI201231487T patent/SI2758071T1/sl unknown
-
2014
- 2014-03-18 IL IL231564A patent/IL231564A0/en active IP Right Grant
- 2014-03-20 ZA ZA2014/02071A patent/ZA201402071B/en unknown
-
2023
- 2023-12-22 US US18/395,150 patent/US20240270829A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2758071T (pt) | 2019-01-11 |
| SG11201400795UA (en) | 2014-10-30 |
| EA201400376A1 (ru) | 2014-09-30 |
| SI2758071T1 (sl) | 2019-01-31 |
| KR20160099732A (ko) | 2016-08-22 |
| EA032494B1 (ru) | 2019-06-28 |
| CA2811188C (en) | 2020-04-28 |
| IL231564A0 (en) | 2014-04-30 |
| MY169574A (en) | 2019-04-22 |
| WO2013044147A1 (en) | 2013-03-28 |
| AU2012312126A1 (en) | 2014-03-27 |
| BR112014006871A2 (pt) | 2017-04-04 |
| NZ622653A (en) | 2015-12-24 |
| PL2758071T3 (pl) | 2019-08-30 |
| ES2712951T3 (es) | 2019-05-16 |
| KR102129220B1 (ko) | 2020-07-02 |
| TR201901846T4 (tr) | 2019-03-21 |
| EP2758071A1 (en) | 2014-07-30 |
| DK2758071T3 (en) | 2019-02-18 |
| CN104039346A (zh) | 2014-09-10 |
| CA2811188A1 (en) | 2013-03-23 |
| JP6110861B2 (ja) | 2017-04-05 |
| MX350928B (es) | 2017-09-26 |
| CN109847058A (zh) | 2019-06-07 |
| HUE041277T2 (hu) | 2019-05-28 |
| AU2012312126B2 (en) | 2016-11-10 |
| US20240270829A1 (en) | 2024-08-15 |
| ZA201402071B (en) | 2017-08-30 |
| KR20190035948A (ko) | 2019-04-03 |
| EP2758071B1 (en) | 2018-11-28 |
| KR20160005380A (ko) | 2016-01-15 |
| JP2014531455A (ja) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX350046B (es) | Tratamientos para trastornos gastrointestinales. | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MY169574A (en) | Vaccine therapy | |
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
| MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
| WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| JO3591B1 (ar) | مدرات الافراز مشتقة من اوكسالوباكتير فورميجينيس | |
| MX2015011775A (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
| EA201391702A1 (ru) | Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
| MX2016001223A (es) | Metodo para el pronostico de la eficacia de la inmunoterapia oral para el tratamiento de la alergia a las proteinas de leche de vaca. | |
| GB201114923D0 (en) | Immunogenic proteins and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |